Start here: real subset, disputed criteria
Two things are true and in tension. There is a real group of long COVID patients whose symptoms match mast cell activation, and their mediator levels can be measured. At the same time, the criteria for calling it a syndrome, including which mediators and what thresholds, are disputed among specialists.
So this page is marked contested, not because the patients are not suffering, but because the field has not agreed on how to define and measure the condition. Honesty about that disagreement protects patients from both dismissal and overdiagnosis.
a real affected subsetlow-moderate gradethresholds and criteria disputed
What mast cells do
Mast cells are immune sentinels in the skin, gut, and airways. When triggered, they degranulate, releasing mediators such as histamine, tryptase, prostaglandin D2, and leukotrienes. Those mediators produce flushing, itching, hives, cramping, diarrhea, and changes in heart rate and blood pressure. Many patients also report new sensitivities to foods, alcohol, medications, and strong smells, the kind of reactivity that points toward mast cells rather than a single organ.
That symptom list overlaps heavily with what many long COVID patients describe, which is why mast cell activation became a leading candidate explanation for a subset. The biology is well understood; the controversy is about measurement and diagnosis.
What the evidence shows
A survey study found that mast cell activation symptoms were common in long COVID and, after COVID, resembled the burden reported by people with diagnosed mast cell activation syndrome. That supports a real and prevalent symptom pattern.
But survey-based and symptom-based evidence is weaker than objective mediator measurement under controlled conditions, and mediator levels are notoriously hard to capture because they spike briefly and degrade fast. The result is suggestive evidence of a real subset rather than a clean, measured diagnosis. A blood draw taken hours after an episode can read normal even when the reaction was real, so a single test cannot exclude the pattern.
survey-based, self-reported
Why the criteria are disputed
Diagnosing mast cell activation rigorously requires showing a rise in specific mediators during an episode and a response to mast cell directed treatment. Strict criteria capture few patients; looser criteria capture many but risk labelling unrelated symptoms.
Specialists disagree on where to draw that line, and long COVID intensifies the disagreement because its symptoms overlap with so many mast cell signs. The dispute is not about whether mast cells exist or matter, but about how to decide who genuinely has activation driving their illness.
Tryptase, the most specific blood marker, is often normal even in people who respond to mast cell treatment, which deepens the disagreement: a normal test does not rule the condition out, and that ambiguity is exactly what makes rigorous diagnosis hard.
What it means for treatment
The practical appeal is that mast cell directed treatments are relatively low risk and available: antihistamines that block H1 and H2 receptors, and mast cell stabilisers. A monitored trial of these is reasonable when activation-type symptoms are prominent.
The honest framing is a therapeutic trial, not a confirmed diagnosis. If symptoms improve, that is useful regardless of the labelling debate. If they do not, the label was probably wrong for that person. Judge it by response, with a clinician, rather than by a contested test result.
How to hold the uncertainty
Avoid both errors. Dismissing mast cell symptoms as anxiety ignores a real, treatable subset. Declaring that everyone with long COVID has mast cell activation syndrome overreaches the evidence and can lead to unnecessary, escalating regimens.
The defensible middle is to take the symptoms seriously, try low-risk mast cell directed treatment where they fit, and stay honest that the diagnostic science is unsettled. That keeps the door open to help without pretending the controversy is resolved.
What we don't know
Honest about the edges of the evidence. These are open questions, not settled answers.
- Which long COVID patients truly have mast cell activation driving their symptoms.
- Which mediators and thresholds best identify the real subset.
- Whether mast cell directed treatment outperforms placebo in long COVID trials.
- Why mast cells become activated after SARS-CoV-2 infection.
- How mast cell activation overlaps with histamine intolerance and allergy.
- How to measure brief mediator spikes reliably in ordinary clinics.
What this means for you
If you have flushing, hives, itching, and gut reactions after COVID, a mast cell pattern is a real possibility, and a monitored trial of low-risk antihistamines and stabilisers is a reasonable conversation to have. Judge it by whether your symptoms improve.
Hold the uncertainty honestly. The affected subset is real and the diagnostic criteria are genuinely disputed, so neither dismissal nor a blanket diagnosis fits. Treat by response with a clinician rather than by a contested test.
References
Each reference links to the source on PubMed, PMC, or the publisher.